oAlert.pl

Recalled Medicines & supplements – Current GIS Alerts 2026

Found 698 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Menaright Forte, Phytomenadion Injection 2mg/0,2 ml – recalled product

Menaright Forte, Phytomenadion Injection 2mg/0,2 ml

CRITICAL 01.09.2022

The glass container shatters when opened, leaving glass fragments in the fingers and inside the ampoule, and differences in the solution volume in ampoules were found. Potential effects: injuries, glass foreign bodies, complications after injection, incorrect drug dose, life‑threatening events.

tianDe Phytotea with Angelica Sinensis and Salvia, 60g – recalled product

tianDe Phytotea with Angelica Sinensis and Salvia, 60g

HIGH 24.08.2022

Chlorpyrifos detected – pesticide residue exceeding the permissible level; substance harmful to health. Potential effects: poisoning, neurological disorders.

Heviran – recalled product

Heviran

HIGH 22.07.2022

A quality defect was found consisting in placing, in some packs of Heviran 400 mg film-coated tablets, a package leaflet in Lithuanian intended for Furosemid Polpharma 40 mg tablets. Potential effects: improper use of the medicine, lack of correct information on dosage, adverse reactions and precautions.

Amiodaron Hameln – recalled product

Amiodaron Hameln

CRITICAL 19.07.2022

Increased crystallization of the product was found in the concentrate for solution for injection or infusion, which may affect the safety and efficacy of intravenous administration. Potential effects: vascular embolism, lack of treatment efficacy, intravenous complications.

Vitaminum C Teva – recalled product

Vitaminum C Teva

CRITICAL 19.07.2022

A result outside specification limits was found for the parameter particles visible to the naked eye in an intramuscular or intravenous injection solution, which may pose a direct risk to patients’ health or life. Potential effects: embolism, inflammatory reactions, circulatory complications.

Tadalafil Aristo – recalled product

Tadalafil Aristo

HIGH 12.07.2022

It cannot be excluded that keeping this medicinal product on the market may pose a risk to patient health, due to identified non-compliances with Good Manufacturing Practice at one manufacturer and the possibility of a quality defect. Potential effects: risk to patient health, possible lack of efficacy or other treatment complications.

Tadalafil Aristo – recalled product

Tadalafil Aristo

MEDIUM 12.07.2022

Non-compliance with Good Manufacturing Practice was found at one of the manufacturers, resulting in suspension of the GMP certificate, so it cannot be excluded that keeping the product on the market may pose a risk to patient health. Potential effects: possible risk to patient health, including lack of treatment efficacy or unpredictable adverse effects.

Structum – recalled product

Structum

HIGH 07.07.2022

Out-of-specification results were found for the TAMC parameter (total aerobic microbial count) and the presence or probability of occurrence of Bacillus cereus was demonstrated. Potential effects: bacterial infection, gastrointestinal symptoms, possible intoxication.

Angusta – recalled product

Angusta

HIGH 28.06.2022

Given that the cause of the out-of-specification result for an unknown impurity and its impact on the product quality and safety of use are currently unknown, it cannot be ruled out that keeping this product on the market may pose a threat to patient health. Potential effects: threat to patient health.

Lactulose-MIP – recalled product

Lactulose-MIP

HIGH 13.06.2022

A risk of microbiological contamination of the active substance used to produce the syrup was identified, resulting in a quality defect of the product and a potential direct threat to patients’ health or life. Potential effects: infection, complications, health risk.

Lactulose-MIP – recalled product

Lactulose-MIP

HIGH 13.06.2022

A risk of microbiological contamination of the active substance used to manufacture the medicinal product was reported, creating a potential threat to patients' health. Potential effects: infections, complications, lack of treatment safety.

Sumilar HCT – recalled product

Sumilar HCT

MEDIUM 02.05.2022

Capsules with an abnormal appearance and colour were identified inside the blister, which constitutes a suspected quality defect of the medicinal product and a potential risk to patients’ health or life. Potential effects: lack of certainty regarding treatment efficacy and safety.

Hemkortin-HC – recalled product

Hemkortin-HC

HIGH 27.04.2022

An error was found in the printed strength of the active substances on the immediate packaging, affecting some tubes in batch D0222, which may lead to incorrect use of the medicine. Potential effects: improper dosing, risk of adverse reactions or lack of treatment efficacy.

Accupro 40 – recalled product

Accupro 40

CRITICAL 25.04.2022

The letter concerned a request for a decision to withdraw the specified batches of medicinal products from the market due to the presence of contamination (N-nitroso-quinapril) above the permitted daily intake limit. Potential effects: possible carcinogenic effects, organ damage, complications of hypertension therapy.

Accupro 10 – recalled product

Accupro 10

HIGH 25.04.2022

detection of contamination (N-nitroso-quinapril) above the acceptable daily intake limit. Potential effects: possible carcinogenic effect and increased risk of adverse reactions.

Accupro 5 – recalled product

Accupro 5

HIGH 25.04.2022

due to the detected presence of contamination (N-nitroso-quinapril) above the acceptable daily intake limit. Potential effects: possible carcinogenic or toxic effects and a health risk for patients.

Vigantol – recalled product

Vigantol

MEDIUM 25.04.2022

Suspected quality defect of the medicinal product resulting from the use of an excipient linked to a batch with an out-of-specification active substance content, which may lead to incorrect dosing of vitamin D. Potential effects: lack of efficacy or adverse effects related to overdose.

Accupro 20 – recalled product

Accupro 20

MEDIUM 25.04.2022

the presence of the impurity (N-nitroso-quinapril) above the acceptable daily intake limit. Potential effects: increased risk of toxicity and carcinogenic effects, especially during long-term use.

NETSPOT – recalled product

NETSPOT

CRITICAL 12.04.2022

A quality defect of the NETSPOT product was identified – stability test results showed the content of the active substance DOTATATE close to the lower limit of the specification, meaning that established quality requirements are not met. Potential effects: lack of diagnostic efficacy, risk of delayed disease diagnosis.

Biotrakson – recalled product

Biotrakson

CRITICAL 12.04.2022

An out-of-specification result for the endotoxin parameter was found in archival samples of an injectable product, which may pose a real and highly probable risk to patients’ health or life. Potential effects: poisoning, severe systemic reactions, septic complications.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.